top of page

ASCO 2026: Bicara Therapeutics is presenting long-term follow up data at ASCO that it believes shows durability derived from choosing TGF-β with EGFR for its fusion protein in HPV negative head & neck

May 31
1 min read

CEO Claire Mazumdar describes the ASCO data, and updates us on the phase 2/3 study, which is already in the phase 3 portion. Bicara hopes to use the study to eventually gain an accelerated approval.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Mispro_Logo_2023_Primary-4.png

Mispro is an AAALAC-accredited contract vivarium organization (CVO) offering a network of full-service vivarium rental lab facilities for preclinical in vivo rodent studies. Along with access to state-of-the-art lab spaces, Mispro supports its clients with comprehensive laboratory animal research services, including husbandry, veterinary, technical, and regulatory compliance oversight. With locations in all major U.S. biotech hubs, Mispro is committed to helping biosciences companies of all sizes and therapeutic indications achieve their research goals.

bottom of page